دورية أكاديمية
Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines.
| العنوان: | Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines. |
|---|---|
| المؤلفون: | Sheehy SH; The Jenner Institute; University of Oxford; Oxford, UK., Douglas AD, Draper SJ |
| المصدر: | Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2013 Sep; Vol. 9 (9), pp. 1831-40. Date of Electronic Publication: 2013 Jun 18. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Philadelphia, PA : Taylor & Francis Original Publication: Austin, Tex. : Landes Bioscience |
| مواضيع طبية MeSH: | Biomedical Research/*methods , Malaria Vaccines/*immunology , Malaria, Falciparum/*immunology , Malaria, Falciparum/*prevention & control , Plasmodium falciparum/*immunology, Humans ; Malaria Vaccines/administration & dosage |
| مستخلص: | In the absence of any highly effective vaccine candidate against Plasmodium falciparum malaria, it remains imperative for the field to pursue all avenues that may lead to the successful development of such a formulation. The development of a subunit vaccine targeting the asexual blood-stage of Plasmodium falciparum malaria infection has proven particularly challenging with only limited success to date in clinical trials. However, only a fraction of potential blood-stage vaccine antigens have been evaluated as targets, and a number of new promising candidate antigen formulations and delivery platforms are approaching clinical development. It is therefore essential that reliable and sensitive methods of detecting, or ruling out, even modest efficacy of blood-stage vaccines in small clinical trials be established. In this article we evaluate the challenges facing blood-stage vaccine developers, assess the appropriateness and limitations of various in vivo approaches for efficacy assessment and suggest future directions for the field. |
| References: | Am J Trop Med Hyg. 2012 Mar;86(3):383-94. (PMID: 22403305) Trends Parasitol. 2012 Nov;28(11):515-21. (PMID: 23041118) Expert Opin Biol Ther. 2008 Apr;8(4):441-8. (PMID: 18352848) PLoS One. 2013 Jun 18;8(6):e65960. (PMID: 23823332) Clin Infect Dis. 2007 Oct 15;45(8):1008-13. (PMID: 17879916) Hum Vaccin. 2010 Jan;6(1):114-23. (PMID: 19946204) Infect Immun. 2006 Aug;74(8):4573-80. (PMID: 16861644) Sci Transl Med. 2011 Jun 22;3(88):88ra56. (PMID: 21697532) Trends Parasitol. 2006 Sep;22(9):424-30. (PMID: 16846756) Nat Rev Immunol. 2011 Jan;11(1):57-64. (PMID: 21179119) J Infect Dis. 2002 Mar 1;185(5):657-64. (PMID: 11865423) Am J Trop Med Hyg. 2013 Jan;88(1):5-13. (PMID: 23149582) Am J Trop Med Hyg. 2008 Mar;78(3):468-71. (PMID: 18337345) N Engl J Med. 2012 Dec 13;367(24):2284-95. (PMID: 23136909) J Infect Dis. 2005 Feb 15;191(4):619-26. (PMID: 15655787) Mol Biochem Parasitol. 2001 Dec;118(2):247-51. (PMID: 11738714) Am J Trop Med Hyg. 2012 Apr;86(4):561-5. (PMID: 22492136) PLoS Med. 2005 Nov;2(11):e344. (PMID: 16262450) Lancet Infect Dis. 2012 Dec;12(12):903-5. (PMID: 23174372) Cell Host Microbe. 2009 Jan 22;5(1):95-105. (PMID: 19154991) Am J Trop Med Hyg. 2005 Jul;73(1):191-8. (PMID: 16014857) Infect Immun. 2005 Jun;73(6):3677-85. (PMID: 15908397) J Infect Dis. 2012 Aug 1;206(3):319-23. (PMID: 22615322) Am J Trop Med Hyg. 1997 Oct;57(4):495-500. (PMID: 9347970) Am J Trop Med Hyg. 2004 Aug;71(2):196-201. (PMID: 15306710) Lancet. 2002 Aug 24;360(9333):610-7. (PMID: 12241933) N Engl J Med. 2011 Sep 15;365(11):1004-13. (PMID: 21916638) Nat Med. 2011 Jan;17(1):49-51. (PMID: 21217684) Am J Trop Med Hyg. 2006 Aug;75(2 Suppl):32-7. (PMID: 16931813) N Engl J Med. 2011 Sep 15;365(11):1062-4. (PMID: 21916656) PLoS One. 2009;4(4):e5254. (PMID: 19390585) PLoS One. 2010 Mar 25;5(3):e9871. (PMID: 20360847) Trends Parasitol. 2011 Jun;27(6):274-83. (PMID: 21531627) Am J Trop Med Hyg. 2013 Jan;88(1):3-4. (PMID: 23303797) Mol Ther. 2012 Dec;20(12):2355-68. (PMID: 23089736) Cytometry A. 2010 Nov;77(11):1067-74. (PMID: 20872885) Trends Parasitol. 2001 Sep;17(9):415-9. (PMID: 11530352) J Infect Dis. 2013 Jul 15;208(2):340-5. (PMID: 23570846) PLoS One. 2009 Dec 03;4(12):e8138. (PMID: 19997632) Trends Parasitol. 2009 May;25(5):205-12. (PMID: 19359219) Lancet. 2008 Nov 1;372(9649):1545-54. (PMID: 18984187) PLoS Pathog. 2012 Feb;8(2):e1002401. (PMID: 22319438) PLoS Pathog. 2012;8(4):e1002665. (PMID: 22532802) J Infect Dis. 2009 Aug 1;200(3):337-46. (PMID: 19569965) Sci Transl Med. 2009 Oct 14;1(2):2ra5. (PMID: 20165550) Lancet. 2008 Nov 1;372(9649):1555-62. (PMID: 18984188) J Clin Invest. 2010 Dec;120(12):4168-78. (PMID: 21123952) Am J Trop Med Hyg. 2008 Jun;78(6):878-83. (PMID: 18541763) Vaccine. 2012 Aug 3;30(36):5302-4. (PMID: 22659449) Hum Vaccin Immunother. 2012 Jun;8(6):706-14. (PMID: 22508415) N Engl J Med. 2011 Nov 17;365(20):1863-75. (PMID: 22007715) Infect Immun. 2011 Mar;79(3):1107-17. (PMID: 21149582) Infect Immun. 2013 Feb;81(2):441-51. (PMID: 23184525) Infect Immun. 2007 Jan;75(1):211-9. (PMID: 17074852) Hum Vaccin. 2010 Aug;6(8):627-34. (PMID: 20519960) PLoS One. 2011;6(5):e20547. (PMID: 21655233) Vaccine. 2000 Mar 17;18(18):1925-31. (PMID: 10699342) J Infect Dis. 2011 May 1;203(9):1337-40. (PMID: 21459819) Parasite Immunol. 2009 Sep;31(9):582-6. (PMID: 19691561) Nature. 2012 Jul 19;487(7407):375-9. (PMID: 22722859) Clin Vaccine Immunol. 2009 Jul;16(7):963-8. (PMID: 19439523) PLoS One. 2011;6(7):e22273. (PMID: 21799810) PLoS One. 2011;6(7):e22271. (PMID: 21799809) PLoS Med. 2010 Jan 19;7(1):e1000218. (PMID: 20098724) J Exp Med. 1990 Dec 1;172(6):1633-41. (PMID: 2258697) Nat Immunol. 2008 Jul;9(7):725-32. (PMID: 18563083) J Exp Med. 2000 Dec 4;192(11):1653-60. (PMID: 11104807) PLoS One. 2012;7(12):e51692. (PMID: 23300556) Lancet. 2012 Feb 4;379(9814):413-31. (PMID: 22305225) Parasite Immunol. 2009 Sep;31(9):520-8. (PMID: 19691556) J Immunol. 2012 May 15;188(10):5041-53. (PMID: 22504652) Science. 2007 Dec 7;318(5856):1544-5. (PMID: 18063766) J Biol Chem. 2004 Mar 5;279(10):9490-6. (PMID: 14676185) PLoS One. 2008 Jan 30;3(1):e1493. (PMID: 18231580) J Clin Invest. 2008 Jan;118(1):342-51. (PMID: 18064303) PLoS One. 2008 Jul 30;3(7):e2830. (PMID: 18665258) Proc Natl Acad Sci U S A. 2011 May 3;108(18):7553-8. (PMID: 21502513) Infect Immun. 1989 Jul;57(7):2043-9. (PMID: 2659533) PLoS One. 2010 Feb 01;5(2):e8988. (PMID: 20126547) Lancet. 2010 Nov 6;376(9752):1515-7. (PMID: 21035845) J Infect Dis. 2002 Mar 15;185(6):820-7. (PMID: 11920300) J Infect Dis. 2009 Dec 1;200(11):1646-9. (PMID: 19877844) PLoS Pathog. 2007 Nov;3(11):e171. (PMID: 17997605) Ann Trop Med Parasitol. 2010 Apr;104(3):189-211. (PMID: 20507694) PLoS One. 2012;7(6):e38434. (PMID: 22701640) Trans R Soc Trop Med Hyg. 2003 Jan-Feb;97(1):53-9. (PMID: 12886806) Nat Commun. 2011 Dec 20;2:601. (PMID: 22186897) Proc Natl Acad Sci U S A. 2013 May 7;110(19):7862-7. (PMID: 23599283) Am J Trop Med Hyg. 2006 Sep;75(3):437-42. (PMID: 16968918) Chem Immunol. 2002;80:204-28. (PMID: 12058640) Vaccine. 2009 Sep 25;27(42):5719-25. (PMID: 19654061) J Infect Dis. 1999 Jun;179(6):1584-6. (PMID: 10228089) |
| معلومات مُعتمدة: | G0700735 United Kingdom MRC_ Medical Research Council; G1000527 United Kingdom MRC_ Medical Research Council; 089455/2/09/Z United Kingdom WT_ Wellcome Trust; 097940/Z/11/Z United Kingdom WT_ Wellcome Trust |
| فهرسة مساهمة: | Keywords: clinical; efficacy; falciparum; malaria; vaccine |
| المشرفين على المادة: | 0 (Malaria Vaccines) |
| تواريخ الأحداث: | Date Created: 20130620 Date Completed: 20140729 Latest Revision: 20220129 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC3906345 |
| DOI: | 10.4161/hv.25383 |
| PMID: | 23778312 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 2164-554X |
|---|---|
| DOI: | 10.4161/hv.25383 |